Aeterna Zentaris is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing, macimorelin, an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency (AGHD), a rare endocrine disorder. Aeterna Zentaris owns the worldwide rights to macimorelin and has significant patent protection left. The Companyâs U.S. composition of matter patent expires in 2022 and our U.S. utility patent runs through 2027. Macimorelin was invented and first synthesized by the research group of Professor Martinez at the University of Montpellier, Centre National de la Recherche Scientitifique (CNRS). This transpired from a long-lasting research collaboration with Aeterna Zentaris. Aeterna Zentaris later in-licensed macimorelin as a development candidate from the CNRS and proceeded with the pre-clinical and clinical development of the compound. On January 17, 2018, Aeterna Zentaris announced that it had, through a wholly-owned subsidiary, entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Ireland Ltd. to carry out development, manufacturing, registration and commercialization of Macrilen⢠(macimorelin) in the United States and Canada. For more information about Macrilen⢠(macimorelin) in the U.S. and Canada visit: www.Strongbridgebio.com. Our licensing agreement of Macrilen⢠for the U.S. and Canada with Strongbridge demonstrates the value of our development initiatives and better positions us to maximize significant value of Macrilen⢠by licensing in territories outside the United States and Canada. Source
No articles found.
Verona Pharma plc is a clinical stage biopharmaceutical company focused on the dev...
Verona Pharma plc is a clinical stage biopharma...
uniQure is delivering on the promise of gene therapy -- single treatments with pot...
uniQure is delivering on the promise of gene th...
Itamar Medical Ltd. is a publicly traded medical device company (TASE:ITMR) based ...
Itamar Medical Ltd. is a publicly traded medica...
Allenaâs lead product candidate, reloxaliase, is a first-in-class, oral enzyme t...
Allenaâs lead product candidate, reloxaliase,...
Akorn, Inc. is a niche pharmaceutical company that develops, manufactures and mark...
Akorn, Inc. is a niche pharmaceutical company t...
Radius is a science-driven fully integrated biopharmaceutical company that is comm...
Radius is a science-driven fully integrated bio...
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the d...
Viking Therapeutics is a clinical-stage biophar...
Join the National Investor Network and get the latest information with your interests in mind.